Table 1 Surgical approaches and postoperative follow-ups of 16 cases of OSFTs
Patient No./Sex | Symptoms | Side | Treatment and Surgical Approach | Tumor location and involvement | Immuno-histochemistry | Progress | Prognosis | Follow-up time, m | |
|---|---|---|---|---|---|---|---|---|---|
CD34 | Ki-67 | ||||||||
1/F | Proptosis; Vision loss | R | Transorbital approach | Inside the muscle cone; lateral wall of the orbit; | + | +(<10 %) | Improvement of the proptosis and vision | Recurrence | 120 |
Proptosis; Vision loss | R | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Improvement of the proptosis and vision | None recurrence | 92 | |
2/F | Proptosis; Vision loss | L | Transorbital approach | Inside the muscle cone; lateral wall of the orbit; | + | +(< 10 %) | Improvement of the proptosis and vision | Recurrence | 34 |
Proptosis; Vision loss | L | Transorbital approach | Inside the muscle cone; lateral wall of the orbit; | + | +(< 10 %) | Improvement of the proptosis and vision | Recurrence | 28 | |
Proptosis; Vision loss | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Improvement of the proptosis and vision | None recurrence | 24 | |
3/M | Proptosis; Visual field defect; Ocular movement disorder | L | Transorbital approach | Inside the muscle cone | + | +(< 10 %) | Improvement of the proptosis | Recurrence | 18 |
Proptosis; Visual field defect; Ocular movement disorder | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; | + | +(< 10 %) | Improvement of the proptosis | None recurrence | 24 | |
4/M | Proptosis; Vision loss | R | Transorbital approach | Inside the muscle cone; lateral wall of the orbit | + | +(< 10 %) | Improvement of the proptosis | Recurrence | 24 |
Proptosis; Blindness | R | Transorbital approach | Inside the muscle cone; lateral wall of the orbit | + | +(< 10 %) | Orbital exenteration | Recurrence | 8 | |
Cranio-orbital mass | R | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure; Subdural brain tissue | + | +(< 20 %) | The mass disappeared | None recurrence | 35 | |
5/F | Proptosis | R | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 5 %) | Improvement of the proptosis | None recurrence | 82 |
6/M | Proptosis | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit | + | +(< 5 %) | Improvement of the proptosis | Recurrence | 228 |
Proptosis; Blindness | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 5 %) | Improvement of the proptosis | None recurrence | 31 | |
7/F | Proptosis | R | Transorbital approach | Outside the muscle cone | + | +(< 10 %) | Improvement of the proptosis | None recurrence | 30 |
8/F | Proptosis; Vision loss; Ocular movement disorder | R | Transorbital approach | Inside the muscle cone; lateral wall of the orbit | + | +(< 10 %) | Improvement of the proptosis | Recurrence | 72 |
Proptosis; Vision loss; Ocular movement disorder | R | Transorbital approach | Inside the muscle cone; lateral wall of the orbit | + | +(< 10 %) | Improvement of the proptosis | Recurrence | 72 | |
Proptosis; Vision loss; Ocular movement disorder | R | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Improvement of the proptosis | None recurrence | 53 | |
9/M | Proptosis; Vision loss; Ocular movement disorder | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Improvement of the proptosis | Recurrence | 54 |
Proptosis; Vision loss; Ocular movement disorder | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Blindness | Recurrence | 45 | |
10/F | Proptosis; Vision loss; | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Blindness | Recurrence | 154 |
Proptosis; Blindness | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Improvement of the proptosis | None recurrence | 43 | |
11/M | Proptosis; Vision loss | L | Transfronto-orbital approach | Inside the muscle cone | + | +(< 5 %) | Improvement of the proptosis | None recurrence | 57 |
12/F | Proptosis; Vision loss | L | Transfronto-orbital approach | Inside the muscle cone | + | +(< 5 %) | Improvement of the proptosis | None recurrence | 74 |
13/F | Proptosis; Vision loss | R | Transorbital approach | Inside the muscle cone | + | +(< 10 %) | Improvement of the proptosis | Recurrence | 36 |
Proptosis; Vision loss; pain | R | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus and superior orbital fissure | + | +(< 10 %) | Improvement of the proptosis | None recurrence | 125 | |
14/M | Proptosis; Vision loss | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus | + | +(< 10 %) | Improvement of the proptosis | None recurrence | 11 |
15/F | Proptosis; Vision loss | L | Transorbital approach | Inside the muscle cone; | + | +(< 10 %) | Improvement of the proptosis and vision | Recurrence | 78 |
Proptosis; Vision loss | L | Transfronto-orbital approach | Inside the muscle cone; lateral wall of the orbit; cavernous sinus | + | +(< 10 %) | Improvement of the proptosis | None recurrence | 30 | |
16/M | Proptosis | L | Transorbital approach | Outside the muscle cone lateral wall of the orbit | + | +(< 5 %) | Improvement of the proptosis | None recurrence | 28 |